Change

Consolidated statement of income


In € millions

2001

2002

20031

2004

20052

2006

2007

20083

2009

2010

 

 

 

 

 

 

 

 

 

 

 

1

The 2001 – 2003 figures have not been restated to IFRS accounting standards. The differences mainly relate to pensions and other post-retirement benefits, the recognition of deferred tax on intercompany profit. and the recognition of goodwill. For the most part, the changed accounting is a matter of timing of the recognition of the assets, liabilities and related results.

2

The 2001 – 2005 figures have not been restated for the Organon BioScences divestment.

3

The 2001 – 2008 figures have not been restated for the National Starch divestment.

4

Not meaningful as operating income was a loss.

Revenue

14,158

14,059

13,106

12,833

13,000

10,023

10,217

15,415

13,028

14,640

Operating income

1,162

1,390

1,146

1,588

1,492

887

778

(577)

855

1,219

Financing income and expenses

(221)

(232)

(248)

(205)

(162)

(134)

(151)

(232)

(405)

(327)

Income tax

(294)

(335)

(254)

(412)

(338)

(96)

(166)

(260)

(141)

(170)

Results from associates and joint ventures

55

30

7

10

6

87

(20)

25

21

25

Profit for the period from continuing operations

702

853

651

981

998

744

441

(1,044)

330

747

Non-controlling interests

(31)

(35)

(49)

(36)

(37)

(29)

(31)

(65)

(77)

(83)

Discontinued operations

438

8,920

23

32

90

Net income attributable to shareholders

671

818

602

945

961

1,153

9,330

(1,086)

285

754

Common shares in millions at year-end

285.9

285.7

285.7

285.8

285.8

287.0

262.3

231.7

232.3

233.5

Dividend

343

343

343

343

343

344

472

417

325

320

Number of employees at year-end

66,300

67,900

64,600

61,400

61,300

42,700

42,600

60,000

54,700

55,600

Salaries, wages and other employee benefits

3,416

3,552

3,505

3,216

3,221

2,158

2,215

3,022

2,955

2,980

Salaries, wages and other employee benefits (in % of revenue)

24.1

25.3

26.7

25.1

24.8

21.5

21.7

19.6

22.7

20.4

Ratios

 

 

 

 

 

 

 

 

 

 

Operating income in percent of revenue

8.2

9.9

8.7

12.4

11.5

8.8

7.6

(3.7)

6.6

8.3

Operating income in percent of invested capital

12.5

15.4

13.6

20.8

19.4

16.3

14.6

4

7.3

9.6

Net income in percent of shareholders’ equity

24.1

32.9

26.2

40.6

32.0

30.5

122.9

4

3.7

8.4

Interest coverage

5.3

6.0

4.6

7.7

9.2

6.6

5.2

4

2.1

3.7

EBITDA coverage

8.3

8.9

7.3

10.5

12.7

9.4

7.5

4

4.2

6.0

Per share information

 

 

 

 

 

 

 

 

 

 

Net income

2.35

2.86

2.11

3.31

3.36

4.02

33.82

(4.38)

1.23

3.23

Dividend

1.20

1.20

1.20

1.20

1.20

1.20

1.80

1.80

1.35

1.40

Shareholders’ equity

10.07

7.34

8.76

9.12

11.95

14.44

42.06

32.21

33.48

38.47

Highest share price during the year

57.85

54.50

32.44

33.79

40.18

49.41

65.56

57.11

46.52

47.70

Lowest share price during the year

33.73

27.25

16.00

24.87

30.82

38.30

44.41

22.85

26.01

37.18

Year-end share price

50.15

30.23

30.60

31.38

39.15

46.18

54.79

29.44

46.40

46.49

Keyword Search
Copyright © 2011 Akzo Nobel N.V.